Generate Biomedicines (GENB) Stock Price, News & Analysis

Company Overview

Generate Biomedicines, Inc. (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates. The company pursues internally discovered programs while also collaborating with biopharmaceutical partners to apply its platform to target-specific problems. Its work spans de novo protein design, engineered biologics and other molecular modalities, with an emphasis on accelerating early-stage development and generating candidates for preclinical advancement.

Headquartered in the United States, Generate serves the broader global biotech and pharmaceutical community through its direct programs and strategic collaborations. The company is publicly traded on the NASDAQ under the ticker GENB and positions itself as a platform-driven innovator in the emerging field often described as generative biology. Management and scientific leadership are built around experience in computational biology and drug discovery, supporting the company’s focus on integrating AI methods into the conventional drug development pipeline.

Key Stats

• Today's Range: $14.42 to $15.47
• 50-Day Range: N/A
• 52-Week Range: $11.00 to $15.47
• Volume: 289,687 shs
• Average Volume: 476,855 shs
• Market Capitalization: $1.97 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.20
• Consensus Rating: Moderate Buy

GENB Stock Analysis - Frequently Asked Questions

How have GENB shares performed this year?

Generate Biomedicines' stock was trading at $12.21 at the beginning of the year. Since then, GENB shares have increased by 26.3% and is now trading at $15.42.

When did Generate Biomedicines IPO?

Generate Biomedicines (GENB) raised $400 million in an IPO on Friday, February 27th 2026. The company issued 25,000,000 shares at $15.00-$17.00 per share.

When did the company's quiet period expire?

Generate Biomedicines's quiet period expired on Wednesday, April 8th. Generate Biomedicines had issued 25,000,000 shares in its public offering on February 27th. The total size of the offering was $400,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Generate Biomedicines?

Shares of GENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GENB
• CIK: 2100782
• Web: N/A
• Phone: (888) 469-0055
• Fax: N/A
• Employees: 312
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Generate Biomedicines: $23.20
• High Price Target: $30.00
• Low Price Target: $16.00
• Potential Upside/Downside: +50.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $31.89 million
• Price / Sales: 61.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 127,450,000
• Free Float: N/A
• Market Cap: $1.97 billion
• Optionable: N/A
• Beta: N/A